t’s an all-too-common story for biotechs trying to cure Alzheimer’s disease (AD).
Despite hundreds of attempts at finding a therapy that can at least slow down AD, we’ve got nothing to show for it but four approved therapies.
None of which addresses the root cause of this increasingly common neurodegenerative condition. All existing therapies only mask the progression of this dreadful disease.
Another One Bites the Dust
The latest to end up on the cutting room floor was a therapy called crenezumab. Crenezumab was under development at Roche and Genentech, and the companies threw in the towel during a recent Phase 3 trial.
Biotechs and Big Pharmas alike have failed again and again to cure Alzheimer’s. It seems many researchers still don’t fundamentally understand this disease yet.
Market Data 
Markets 
AI
